211 related articles for article (PubMed ID: 34911567)
1. CBD-enriched cannabis for autism spectrum disorder: an experience of a single center in Turkey and reviews of the literature.
Bilge S; Ekici B
J Cannabis Res; 2021 Dec; 3(1):53. PubMed ID: 34911567
[TBL] [Abstract][Full Text] [Related]
2. Effects of CBD-Enriched
Fleury-Teixeira P; Caixeta FV; Ramires da Silva LC; Brasil-Neto JP; Malcher-Lopes R
Front Neurol; 2019; 10():1145. PubMed ID: 31736860
[TBL] [Abstract][Full Text] [Related]
3. Cannabidiol in Treatment of Autism Spectrum Disorder: A Case Study.
Ma L; Platnick S; Platnick H
Cureus; 2022 Aug; 14(8):e28442. PubMed ID: 36176817
[TBL] [Abstract][Full Text] [Related]
4. Cannabinoid treatment for the symptoms of autism spectrum disorder.
Aran A; Cayam Rand D
Expert Opin Emerg Drugs; 2024 Mar; 29(1):65-79. PubMed ID: 38226593
[TBL] [Abstract][Full Text] [Related]
5. Individually tailored dosage regimen of full-spectrum Cannabis extracts for autistic core and comorbid symptoms: a real-life report of multi-symptomatic benefits.
Montagner PSS; Medeiros W; da Silva LCR; Borges CN; Brasil-Neto J; de Deus Silva Barbosa V; Caixeta FV; Malcher-Lopes R
Front Psychiatry; 2023; 14():1210155. PubMed ID: 37671290
[TBL] [Abstract][Full Text] [Related]
6. Cannabidiol is a behavioral modulator in BTBR mouse model of idiopathic autism.
Shrader SH; Mellen N; Cai J; Barnes GN; Song ZH
Front Neurosci; 2024; 18():1359810. PubMed ID: 38784096
[TBL] [Abstract][Full Text] [Related]
7. Clinical and Family Implications of Cannabidiol (CBD)-Dominant Full-Spectrum Phytocannabinoid Extract in Children and Adolescents with Moderate to Severe Non-Syndromic Autism Spectrum Disorder (ASD): An Observational Study on Neurobehavioral Management.
Mazza JAS; Ferreira LS; Martins-Vieira AF; Beserra DDL; Rodrigues VA; Malcher-Lopes R; Caixeta FV
Pharmaceuticals (Basel); 2024 May; 17(6):. PubMed ID: 38931353
[TBL] [Abstract][Full Text] [Related]
8. Medical cannabis for the treatment of comorbid symptoms in children with autism spectrum disorder: An interim analysis of biochemical safety.
Stolar O; Hazan A; Vissoker RE; Kishk IA; Barchel D; Lezinger M; Dagan A; Treves N; Meiri D; Berkovitch M; Kohn E; Heyman E
Front Pharmacol; 2022; 13():977484. PubMed ID: 36249785
[No Abstract] [Full Text] [Related]
9. Safety and Efficacy of Medical Cannabis in Autism Spectrum Disorder Compared with Commonly Used Medications.
Holdman R; Vigil D; Robinson K; Shah P; Contreras AE
Cannabis Cannabinoid Res; 2022 Aug; 7(4):451-463. PubMed ID: 34432543
[No Abstract] [Full Text] [Related]
10. Chronic Adolescent Δ
Murphy M; Mills S; Winstone J; Leishman E; Wager-Miller J; Bradshaw H; Mackie K
Cannabis Cannabinoid Res; 2017; 2(1):235-246. PubMed ID: 29098186
[No Abstract] [Full Text] [Related]
11. Cannabidiol as a suggested candidate for treatment of autism spectrum disorder.
Poleg S; Golubchik P; Offen D; Weizman A
Prog Neuropsychopharmacol Biol Psychiatry; 2019 Mar; 89():90-96. PubMed ID: 30171992
[TBL] [Abstract][Full Text] [Related]
12. Behavioral aspects and neurobiological properties underlying medical cannabis treatment in Shank3 mouse model of autism spectrum disorder.
Poleg S; Kourieh E; Ruban A; Shapira G; Shomron N; Barak B; Offen D
Transl Psychiatry; 2021 Oct; 11(1):524. PubMed ID: 34645786
[TBL] [Abstract][Full Text] [Related]
13. Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of pediatric epilepsy: A potential role for infantile spasms and Lennox-Gastaut syndrome.
Hussain SA; Zhou R; Jacobson C; Weng J; Cheng E; Lay J; Hung P; Lerner JT; Sankar R
Epilepsy Behav; 2015 Jun; 47():138-41. PubMed ID: 25935511
[TBL] [Abstract][Full Text] [Related]
14. The Potential of Salivary Lipid-Based Cannabis-Responsive Biomarkers to Evaluate Medical Cannabis Treatment in Children with Autism Spectrum Disorder.
Siani-Rose M; McKee R; Cox S; Goldstein B; Abrams D; Taylor M; Kurek I
Cannabis Cannabinoid Res; 2023 Aug; 8(4):642-656. PubMed ID: 35343818
[No Abstract] [Full Text] [Related]
15. Brief Report: Cannabidiol-Rich Cannabis in Children with Autism Spectrum Disorder and Severe Behavioral Problems-A Retrospective Feasibility Study.
Aran A; Cassuto H; Lubotzky A; Wattad N; Hazan E
J Autism Dev Disord; 2019 Mar; 49(3):1284-1288. PubMed ID: 30382443
[TBL] [Abstract][Full Text] [Related]
16. The protocol for the Cannabidiol in children with refractory epileptic encephalopathy (CARE-E) study: a phase 1 dosage escalation study.
Reithmeier D; Tang-Wai R; Seifert B; Lyon AW; Alcorn J; Acton B; Corley S; Prosser-Loose E; Mousseau DD; Lim HJ; Tellez-Zenteno J; Huh L; Leung E; Carmant L; Huntsman RJ
BMC Pediatr; 2018 Jul; 18(1):221. PubMed ID: 29981580
[TBL] [Abstract][Full Text] [Related]
17. Children and adolescents with ASD treated with CBD-rich cannabis exhibit significant improvements particularly in social symptoms: an open label study.
Hacohen M; Stolar OE; Berkovitch M; Elkana O; Kohn E; Hazan A; Heyman E; Sobol Y; Waissengreen D; Gal E; Dinstein I
Transl Psychiatry; 2022 Sep; 12(1):375. PubMed ID: 36085294
[TBL] [Abstract][Full Text] [Related]
18. Opposite Roles for Cannabidiol and δ-9-Tetrahydrocannabinol in Psychotomimetic Effects of Cannabis Extracts: A Naturalistic Controlled Study.
Sainz-Cort A; Jimenez-Garrido D; Muñoz-Marron E; Viejo-Sobera R; Heeroma J; Bouso JC
J Clin Psychopharmacol; 2021 Sep-Oct 01; 41(5):561-570. PubMed ID: 34412109
[TBL] [Abstract][Full Text] [Related]
19. The Impact of THC and CBD in Schizophrenia: A Systematic Review.
Ahmed S; Roth RM; Stanciu CN; Brunette MF
Front Psychiatry; 2021; 12():694394. PubMed ID: 34366924
[No Abstract] [Full Text] [Related]
20. The effect of cannabidiol (CBD) on low-frequency activity and functional connectivity in the brain of adults with and without autism spectrum disorder (ASD).
Pretzsch CM; Voinescu B; Mendez MA; Wichers R; Ajram L; Ivin G; Heasman M; Williams S; Murphy DG; Daly E; McAlonan GM
J Psychopharmacol; 2019 Sep; 33(9):1141-1148. PubMed ID: 31237191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
